PCBD2

Across TCGA pan-cancer cohorts, PCBD2 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of PCBD2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where PCBD2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PCBD2 is over-expressed in tumor, although a few such as HNSC and COAD show the opposite, repressed pattern.

HNSC, COAD, and LSCC are the cancer types where PCBD2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PCBD2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	II,III,IV	−0.859	<.001	11	view →
COAD	Female	II,III,IV	−0.219	<.001	10	view →
LSCC	Male	All	−0.591	<.001	9	view →
LUAD	Male	III,IV	−0.457	<.001	9	view →
PDAC	Female	All	−0.487	.008	4	view →
CCRCC	Male	II,III,IV	+0.154	.011	3	view →
OV	All	All	−0.411	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

PCBD2–HNSC

Open the HNSC breakdown →